ID   J82-NVB
AC   CVCL_4V98
DR   cancercelllines; CVCL_4V98
DR   Wikidata; Q54898492
RX   PubMed=7981063;
RX   PubMed=9137463;
CC   Population: Caucasian; Swedish.
CC   Doubling time: 19 + 4 hours (PubMed=9137463).
CC   Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; NVB).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0359 ! J82
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=7981063; DOI=10.1038/bjc.1994.458;
RA   Debal V., Allam N., Morjani H., Millot J.-M., Braguer D., Breillout F.,
RA   Manfait M.;
RT   "Characterisation of a navelbine-resistant bladder carcinoma cell line
RT   cross-resistant to taxoids.";
RL   Br. J. Cancer 70:1118-1125(1994).
//
RX   PubMed=9137463;
RA   Debal V., Breillout F., Manfait M.;
RT   "Concomitant decrease of resistance and modifications of the
RT   cytoskeleton after all-trans retinoic acid and phorbol ester
RT   treatments in a navelbine-resistant bladder carcinoma cell line.";
RL   Anticancer Res. 17:1147-1154(1997).
//